Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.36
Schlusskurs vom Vortag:
$4.36
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$96.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-94.11M
KGV:
0.00
EPS:
-6.01
Netto-Cashflow:
$-86.06M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$4.3785
52-Wochen-Spanne:
$0.00
$6.07
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Firmenname
Adverum Biotechnologies Inc
Sektor
Branche
Telefon
(650) 649-1004
Adresse
100 CARDINAL WAY, REDWOOD CITY, CA
Vergleichen Sie ADVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
0.00 | 96.26M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Hochstufung | Truist | Hold → Buy |
| 2021-07-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Herabstufung | Truist | Buy → Hold |
| 2020-12-16 | Eingeleitet | UBS | Neutral |
| 2020-11-12 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-05 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-09-13 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-06-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2018-11-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Herabstufung | SunTrust | Buy → Hold |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Eingeleitet | SunTrust | Buy |
| 2018-02-15 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Adverum Biotechnologies Inc Aktie (ADVM) Neueste Nachrichten
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - The Malaysian Reserve
Eli Lilly (LLY) Completes Acquisition of Adverum Biotechnologies - GuruFocus
Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies - Nasdaq
Lilly completes tender offer for Adverum Biotechnologies - Investing.com
Monday’s Insider Moves: Adverum Execs Lead Buys, Diamondback Sale Tops - Investing.com Australia
Adverum Biotechnologies Stock (ADVM) Opinions on Lilly Acquisition - Quiver Quantitative
Lilly completes tender offer for Adverum Biotechnologies By Investing.com - Investing.com UK
Lilly completes Adverum acquisition for $3.56 per share plus CVRs - StreetInsider
Adverum Biotechnologies (NASDAQ:ADVM) CEO Buys $47,000.40 in Stock - MarketBeat
Insider Buying: Laurent Fischer Acquires Shares of Adverum Biote - GuruFocus
Soparkar Peter, Adverum Biotechnologies COO, buys $211k in shares By Investing.com - Investing.com Canada
Adverum biotechnologies CEO Fischer buys shares worth $553916 By Investing.com - Investing.com Canada
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock - Defense World
Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock - MarketBeat
What analysts say about Adverum Biotechnologies Inc stockEarnings Per Share Trends & Try Our Free Strategy Builder Now - earlytimes.in
Owner Leonard Sells 524,560 ($2.2M) Of Adverum Biotechnologies Inc [ADVM] - TradingView
Adverum Reminds Stockholders to Tender Their Shares Into the Offer by Lilly - 富途牛牛
LUNA Surges 20% in a Day Amid Ongoing Terra Network Upgrade - Bitget
Why retail traders accumulate Adverum Biotechnologies Inc. (AVU0) stockWeekly Profit Report & Advanced Swing Trade Entry Alerts - Newser
Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells 222,925 Shares of Stock - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Sells 51,961 Shares - MarketBeat
Adverum Biotechnologies Releases Promising Phase 2 Trial Data - TipRanks
Adverum Biotechnologies, Inc. Announces Two-Year Data from LUNA Phase 2 Trial - TradingView
How Adverum Biotechnologies Inc. (AVU0) stock reacts to stronger dollarJuly 2025 Highlights & Growth Oriented Trade Recommendations - Newser
Why Adverum Biotechnologies Inc. (AVU0) stock trades below fair valueMarket Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Is Adverum Biotechnologies Inc. (AVU0) stock resilient in recession scenariosQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Adverum Biotechnologies releases promising phase 2 trial data - MSN
Leonard of Adverum Bio sells $2.4m in shares By Investing.com - Investing.com Canada
Owner Leonard Sells 574,886 ($2.4M) Of Adverum Biotechnologies Inc [ADVM] - TradingView
Is Adverum Biotechnologies Inc. (AVU0) stock undervalued by metricsJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Published on: 2025-12-02 05:06:35 - Newser
What technical patterns form on Adverum Biotechnologies Inc. (AVU0) stock charts - Newser
Will Adverum Biotechnologies Inc. (AVU0) stock return to pre crash levelsMarket Growth Review & Consistent Profit Trading Strategies - Newser
How Adverum Biotechnologies Inc. (AVU0) stock performs in volatility spikesQuarterly Market Review & Precise Trade Entry Recommendations - Newser
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns - Investing.com Canada
Adverum reminds stockholders to tender their shares into the offer by Lilly - marketscreener.com
Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnolo - GuruFocus
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns By Investing.com - Investing.com South Africa
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biote - The National Law Review
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Adverum Biotechnologies Faces Lease Termination Notice - TipRanks
Adverum Biotechnologies IncARE-NC Region No. 21 LLC terminates certain lease agreement with Adverum BiotechnologiesSEC filing - MarketScreener
[8-K] Adverum Biotechnologies, Inc. Reports Material Event | ADVM SEC FilingForm 8-K - Stock Titan
Lilly strengthens gene therapy portfolio with MeiraGTx and Adverum deals - Drug Discovery News
Chart overlay techniques for tracking Adverum Biotechnologies Inc.2025 Price Targets & Low Risk Growth Stock Ideas - newser.com
Is Adverum Biotechnologies Inc. stock cheap compared to fundamentals2025 Retail Activity & Weekly High Momentum Picks - newser.com
Why Adverum Biotechnologies Inc. stock remains on watchlistsJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Adverum Biotechnologies (ADVM) Price Target Decreased by 11.61% to 10.10 - MSN
Will Adverum Biotechnologies Inc. stock maintain growth storyMarket Growth Report & Safe Swing Trade Setups - newser.com
HC Wainwright Analysts Decrease Earnings Estimates for ADVM - MarketBeat
Finanzdaten der Adverum Biotechnologies Inc-Aktie (ADVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):